HIGHLIGHTS
- who: TYPE et al. from the Peking University, China have published the article: Recent advances in targeting protein kinases and pseudokinases in cancer biology, in the Journal: (JOURNAL)
SUMMARY
To type I inhibitors, there are type 1.5 inhibitors such as the RAF inhibitor vemurafenib, which are ATP-competitive inhibitors, that bind the kinase with a DFG "in" but α-helix "out" conformation (Tsai et_al, 2008; Fabbro et_al, 2015). Besides playing critical roles in host defense and autoimmunity, JAKs are associated with cancers especially hematologic malignancies (James et_al, 2005; Levine et_al, 2005; Erdogan et_al . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.